BioCentury
ARTICLE | Company News

Attenuon, Xoma Ltd. deal

October 9, 2006 7:00 AM UTC

XOMA will use its Human Engineering technology to humanize Attenuon's lead murine antibody targeting the urokinase-type plasminogen activator ( uPA) system to treat cancer. XOMA will receive an upfro...